SKYE vs. TSVT, INZY, GLUE, PVLA, LFCR, TNGX, GOSS, CRVS, AQST, and AVIR
Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include 2seventy bio (TSVT), Inozyme Pharma (INZY), Monte Rosa Therapeutics (GLUE), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Aquestive Therapeutics (AQST), and Atea Pharmaceuticals (AVIR). These companies are all part of the "pharmaceutical products" industry.
Skye Bioscience vs.
2seventy bio (NASDAQ:TSVT) and Skye Bioscience (NASDAQ:SKYE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, community ranking, analyst recommendations and dividends.
2seventy bio presently has a consensus target price of $4.25, suggesting a potential downside of 15.00%. Skye Bioscience has a consensus target price of $16.60, suggesting a potential upside of 651.13%. Given Skye Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Skye Bioscience is more favorable than 2seventy bio.
2seventy bio has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500. Comparatively, Skye Bioscience has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500.
In the previous week, Skye Bioscience had 4 more articles in the media than 2seventy bio. MarketBeat recorded 8 mentions for Skye Bioscience and 4 mentions for 2seventy bio. 2seventy bio's average media sentiment score of 1.63 beat Skye Bioscience's score of 0.51 indicating that 2seventy bio is being referred to more favorably in the media.
Skye Bioscience has lower revenue, but higher earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than Skye Bioscience, indicating that it is currently the more affordable of the two stocks.
93.9% of 2seventy bio shares are held by institutional investors. Comparatively, 21.1% of Skye Bioscience shares are held by institutional investors. 7.2% of 2seventy bio shares are held by company insiders. Comparatively, 3.0% of Skye Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
2seventy bio received 10 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 44.64% of users gave 2seventy bio an outperform vote.
Skye Bioscience has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. Skye Bioscience's return on equity of -45.78% beat 2seventy bio's return on equity.
Summary
Skye Bioscience beats 2seventy bio on 9 of the 17 factors compared between the two stocks.
Get Skye Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skye Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:SKYE) was last updated on 5/22/2025 by MarketBeat.com Staff
